Thought Leadership Weighing the Evidence: JAK Safety, OX40/OX40L Biology, and the Medical Communications Gap in Dermatology
Thought Leadership Four emerging layers of clinical complexity in oncology, and what they mean for Medical Affairs
Thought Leadership The evolution of biologics: Why mechanism differentiation is now the central communications challenge in dermatology
Thought Leadership The patient activation window is closing — and most pharma is still building yesterday’s system